Enliven Therapeutics Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
31.00
|
|
Average Rating
|
5.00
|
|
# Strong Buys
|
3
|
|
# Buys
|
0
|
|
# Holds
|
0
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2023-09-30
|
-0.47
|
-0.51
|
-0.04
|
-8.51%
|
|
2023-06-30
|
-0.36
|
-0.41
|
-0.05
|
-13.89%
|
|
2023-03-31
|
-0.63
|
-0.80
|
-0.17
|
-26.98%
|
|
2022-12-31
|
-0.79
|
1.21
|
2.00
|
253.94%
|
|
2022-09-30
|
-1.00
|
-0.72
|
0.28
|
28.00%
|
|
2022-06-30
|
-2.05
|
-1.76
|
0.29
|
14.15%
|
|
2022-03-31
|
-2.31
|
-2.24
|
0.07
|
3.03%
|
|
2021-12-31
|
-3.00
|
-2.12
|
0.88
|
29.33%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2023-12-31
|
-1.72
|
|
2022-12-31
|
-3.51
|
|
2021-12-31
|
-9.60
|
|
2020-12-31
|
-24.72
|
|
2019-12-31
|
-1.00
|